Related Experiment Video
Updated: Mar 7, 2026
A Minimally Invasive Method for Generating a Syngeneic Orthotopic Mouse Model of Lung Cancer
Published on: August 19, 2025
[Improving the internal medical care to set up a leading model for precision medicine development in lung cancer]
1Department of Pulmonary Medicine, Shanghai Chest Hospital & Chest Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200030, China.
Abstract:
Lung cancer still remains the leading cause of cancer-related death worldwide. Recent development of molecular targeted therapies, especially the emergence of epidermal growth factor receptor (EGFR) inhibitors, has made an enormous progress for the treatment of non-small cell lung cancer (NSCLC). However, targeted therapy still faces many problems including acquired resistance. Several clinical trials have proved that targeted therapy can significantly improve the progression-free survival (PFS), but there are still many things needed to be improved. Thus, oncologists still have a long way to go for realizing precision medicine. The present article illustrates the impact of precision medicine on the treatment of lung cancer and describes how to improve the treatment level of lung cancer, aiming to give an inspiration to the medical oncologists.
Insights
Precision medicine, including epidermal growth factor receptor (EGFR) inhibitors, has advanced non-small cell lung cancer (NSCLC) treatment. Further improvements are needed to overcome challenges like acquired resistance and achieve true precision medicine in lung cancer care.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Lung cancer is a leading cause of cancer mortality globally.
- Molecular targeted therapies, particularly EGFR inhibitors, have improved non-small cell lung cancer (NSCLC) treatment.
- Acquired resistance remains a significant challenge in targeted cancer therapy.
Purpose of the Study:
- To illustrate the impact of precision medicine on lung cancer treatment.
- To describe strategies for improving lung cancer treatment levels.
- To inspire oncologists towards advancing precision medicine.
Main Methods:
- Review of clinical trials and therapeutic outcomes.
- Analysis of challenges in targeted therapy for NSCLC.
- Discussion of precision medicine principles in oncology.
Main Results:
- Targeted therapy, including EGFR inhibitors, significantly improves progression-free survival (PFS) in NSCLC.
- Acquired resistance limits the long-term efficacy of current targeted treatments.
- Precision medicine offers a framework for optimizing lung cancer therapy.
Conclusions:
- Precision medicine holds significant promise for advancing lung cancer treatment.
- Overcoming acquired resistance is crucial for maximizing the benefits of targeted therapies.
- Continued innovation is essential for achieving personalized and effective lung cancer care.
More Related Videos
11:31Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
Published on: May 20, 2016
06:03Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
